部分国家丙型肝炎病毒（HCV）的历史流行病学——第3卷

Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.

作者信息

Liakina V, Hamid S, Tanaka J, Olafsson S, Sharara A I, Alavian S M, Gheorghe L, El Hassan E S, Abaalkhail F, Abbas Z, Abdou A, Abourached A, Al Braiki F, Al Hosani F, Al Jaberi K, Al Khatry M, Al Mulla M A, Al Quraishi H, Al Rifai A, Al Serkal Y, Alam A, Alashgar H I, Alawadhi S, Al-Dabal L, Aldins P, Alfaleh F Z, Alghamdi A S, Al-Hakeem R, Aljumah A A, Almessabi A, Alqutub A N, Alswat K A, Altraif I, Alzaabi M, Andrea N, Assiri A M, Babatin M A, Baqir A, Barakat M T, Bergmann O M, Bizri A R, Blach S, Chaudhry A, Choi M S, Diab T, Djauzi S, El Khoury S, Estes C, Fakhry S, Farooqi J I, Fridjonsdottir H, Gani R A, Ghafoor Khan A, Goldis A, Gottfredsson M, Gregorcic S, Hajarizadeh B, Han K H, Hasan I, Hashim A, Horvath G, Hunyady B, Husni R, Jafri W, Jeruma A, Jonasson J G, Karlsdottir B, Kim D Y, Kim Y S, Koutoubi Z, Lesmana L A, Lim Y S, Löve A, Maimets M, Makara M, Malekzadeh R, Matičič M, Memon M S, Merat S, Mokhbat J E, Mourad F H, Muljono D H, Nawaz A, Nugrahini N, Priohutomo S, Qureshi H, Rassam P, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Rozentale B, Sadik M, Saeed K, Salamat A, Salupere R, Sanai F M, Sanityoso Sulaiman A, Sayegh R A, Schmelzer J D, Sibley A, Siddiq M, Siddiqui A M, Sigmundsdottir G, Sigurdardottir B, Speiciene D, Sulaiman A, Sultan M A, Taha M, Tarifi H, Tayyab G, Tolmane I, Ud Din M, Umar M, Valantinas J, Videčnik-Zorman J, Yaghi C, Yunihastuti E, Yusuf M A, Zuberi B F, Gunter J

机构信息

Centre of Hepatology, Gastroenterology, and Dietetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Department of Biomechanics, Vilnius Gediminas Technical University, Vilnius, Lithuania.

出版信息

J Viral Hepat. 2015 Dec;22 Suppl 4:4-20. doi: 10.1111/jvh.12475.

DOI:10.1111/jvh.12475

PMID:26513445

Abstract

Detailed, country-specific epidemiological data are needed to characterize the burden of chronic hepatitis C virus (HCV) infection around the world. With new treatment options available, policy makers and public health officials must reconsider national strategies for infection control. In this study of 15 countries, published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates were gathered from the literature and validated by expert consensus in each country. Viraemic prevalence in this study ranged from 0.2% in Iran and Lebanon to 4.2% in Pakistan. The largest viraemic populations were in Pakistan (7 001 000 cases) and Indonesia (3 187 000 cases). Injection drug use (IDU) and a historically unsafe blood supply were major risk factors in most countries. Diagnosis, treatment and liver transplant rates varied widely between countries. However, comparison across countries was difficult as the number of cases changes over time. Access to reliable data on measures such as these is critical for the development of future strategies to manage the disease burden.

摘要

需要详细的、针对特定国家的流行病学数据来描述全球慢性丙型肝炎病毒（HCV）感染的负担。随着新的治疗方案的出现，政策制定者和公共卫生官员必须重新考虑国家感染控制策略。在这项对15个国家的研究中，从文献中收集了关于HCV流行率、病毒血症、基因型、年龄和性别分布、肝移植以及诊断和治疗率的已发表和未发表数据，并在每个国家通过专家共识进行了验证。本研究中的病毒血症流行率从伊朗和黎巴嫩的0.2%到巴基斯坦的4.2%不等。病毒血症人口最多的是巴基斯坦（700.1万例）和印度尼西亚（318.7万例）。在大多数国家，注射吸毒（IDU）和历史上不安全的血液供应是主要危险因素。各国之间的诊断、治疗和肝移植率差异很大。然而，由于病例数量随时间变化，各国之间的比较很困难。获取有关此类措施的可靠数据对于制定未来管理疾病负担的策略至关重要。